MUC1-BH3 Protein Interaction Inhibition via Small Molecule Mediators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate the interactions between MUC1 and BH3-containing proapoptotic proteins, which are crucial for regulating apoptosis in cancer and immune cells, limiting therapeutic options for cancer and inflammatory conditions.
Innovation Solution
A method is developed to identify and manufacture compounds that inhibit the binding of MUC1 to BH3-containing proapoptotic proteins, such as BID, BAX, and BIM, using a three-dimensional structure-based approach to design molecules that disrupt these interactions, and subsequently promote apoptosis in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MUC1 is overexpressed to induce transformation and attenuate apoptosis, then cell survival is improved, but cancer progression is worsened
Solution Approach 1:
The invention extracts and isolates the BH3-containing proapoptotic proteins (BID, BAX, BIM) that are sequestered by MUC1. By removing these proteins from the MUC1 complex, the patent restores apoptotic function while leaving MUC1 expression intact, thereby resolving the contradiction between maintaining cell survival signals and eliminating cancer progression
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that disrupt the MUC1-BH3 protein interaction. These compounds act as mediators that prevent MUC1 from binding to and inactivating the proapoptotic proteins, thereby restoring apoptosis without directly targeting MUC1 itself
2Reliability
If MUC1-C is targeted to mitochondria to block release of apoptogenic proteins, then anti-apoptotic function is improved, but therapeutic vulnerability is worsened
Solution Approach 1:
Small molecule compounds serve as intermediaries that specifically disrupt the interaction between MUC1-C and BH3-containing proapoptotic proteins at the mitochondrial level. This restores apoptotic function selectively in MUC1-expressing cells without affecting normal cells, thereby creating therapeutic vulnerability
Solution Approach 2:
The invention targets the specific mitochondrial localization of MUC1-C and its interaction with BH3 proteins. By focusing the therapeutic action at this specific subcellular location and molecular interface, the patent restores anti-apoptotic function locally without broadly affecting cellular physiology, creating selective therapeutic vulnerability
3Reliability
If compounds are designed to inhibit MUC1-BH3 interactions, then apoptosis induction is improved, but manufacturing complexity is worsened
Solution Approach 1:
The patent employs high-throughput screening methods that systematically vary compound parameters (chemical structure, concentration, binding affinity) to identify effective inhibitors. This parameter-based approach enables the discovery of manufacturable compounds with optimized properties that balance apoptosis induction efficacy with manufacturing feasibility
Data Source
AI summary
This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or immune cell growth. The invention provides methods of inhibiting interactions between MUC1 and BH3-containing proapoptotic proteins, methods of inhibiting MUC1 expression, and methods of promoting apoptosis. Also provided are screening methods for compounds that inhibit interactions between MUC1 and BH3-containing proapoptotic proteins and pharmaceutical compositions of the same.